Testosterone for type 2 diabetes prevention in men: A 2-year multicentre, randomised, double-blind, placebo-controlled trial

Gary Wittert, Evan Atlantis, Mathis Grossmann, Bu B. Yeap, Ann Conway, Bronwyn Stuckey, David Handelsman, Robert McLachlan, Carolyn Allan, Alicia Jenkins, Mark Daniel, Karen Bracken

    Research output: Contribution to journalMeeting Abstract

    Abstract

    Background: Low serum testosterone level is associated with in-creased risk of type 2 diabetes (T2D) in overweight men with im-paired glucose tolerance (IGT). It is not known whether testosterone (T) treatment is effective and safe for preventing T2D in this high- risk group.Aim: To determine in a large, multicentre, double- blinded placebo- controlled RCT, whether T treatment combined with lifestyle inter-vention (Weight Watchers®) as compared to lifestyle intervention alone, reduces T2D at 2 years.
    Original languageEnglish
    Pages (from-to)47-48
    Number of pages2
    JournalClinical Endocrinology
    Volume89
    Issue numberS1
    Publication statusPublished - Jun 2018

    Cite this

    Wittert, G., Atlantis, E., Grossmann, M., Yeap, B. B., Conway, A., Stuckey, B., ... Bracken, K. (2018). Testosterone for type 2 diabetes prevention in men: A 2-year multicentre, randomised, double-blind, placebo-controlled trial. Clinical Endocrinology, 89(S1), 47-48.